|
Concordance between CA-125 and RECIST progression (PD) in patients with germline BRCA-mutated platinum-sensitive, relapsed ovarian cancer treated with a PARP inhibitor (PARPi) as maintenance therapy after response to chemotherapy. |
|
|
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim |
|
|
Honoraria - AstraZeneca; Lilly; MSD; Novartis; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Lilly; MSD; Novartis; Takeda |
Speakers' Bureau - ACT Genomics; AstraZeneca |
Research Funding - AstraZeneca (Inst); BeiGene (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Tesaro |
Travel, Accommodations, Expenses - PharmaMar; Roche; Tesaro |
|
|
Honoraria - AstraZeneca/MedImmune |
Consulting or Advisory Role - Artios; AstraZeneca/MedImmune; Clovis Oncology; Cristal Therapeutics; Eisai; Merck; Pfizer; Seagen; Tesaro |
Speakers' Bureau - Clovis Oncology; Pfizer; Tesaro/GSK |
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst) |
Travel, Accommodations, Expenses - Clovis Oncology |
Other Relationship - Regeneron |
|
|
Honoraria - Abbvie; AstraZeneca; Clovis Oncology; Eisai; Genentech/Roche; Janssen Oncology; Mersana; Newlink Genetics; Sutter Medical Group; Tesaro; Vascular Biogenics |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Baxalta; Care4ward; Clovis Oncology; Eisai; Genentech; Janssen Oncology; Merck; Mersana; Sutter Medical Group; Tesaro; Vascular Biogenics |
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Cerulean Pharma (Inst); Eisai (Inst); Genentech (Inst); Regeneron (Inst); Sanofi (Inst); Tesaro (Inst); Vascular Biogenics (Inst) |
Patents, Royalties, Other Intellectual Property - Blackwell Publishing; BMJ; UpToDate |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Genentech; Tesaro; Vascular Biogenics |
Other Relationship - Abbvie |
|
|
|
Consulting or Advisory Role - Immunogen; Merck KGaA |
Research Funding - AstraZeneca (Inst); Immunovaccine (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
Other Relationship - AstraZeneca; Clovis Oncology; Clovis Oncology; Merck; Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; MSD Oncology |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Tesaro |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche/Genentech; Tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; GlaxoSmithKline; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech; Takeda; Tesaro |
|
|
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Hexal; Lilly; Roche; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer; Roche; Tesaro |
|
|
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical |
Consulting or Advisory Role - Abbvie; AstraZeneca; Eisai; Genmab; MSD; Pfizer; Taiho Pharmaceutical; Takeda |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Shionogi (Inst); Zeria Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Abbvie; MSD; Pfizer |
|
|
Consulting or Advisory Role - Novartis (Inst) |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Carrick Therapeutics (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Medical University of Vienna (Inst); Millennium (Inst); MSD Belgium (Inst); Octimet (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst) |
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; MSD/Merck; Roche; Tesaro |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; GlaxoSmithKline; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Incyte; Merck; Pfizer/EMD Serono; Roche; TESARO |
Travel, Accommodations, Expenses - AstraZeneca; Roche; Tesaro |
Other Relationship - Arcagy-Gineco |